NSC666715 and Its analogs inhibit strand-displacement activity of DNA polymerase β and potentiate temozolomide-induced DNA damage, senescence and apoptosis in colorectal cancer cells

Aruna S. Jaiswal, Harekrushna Panda, Brian K. Law, Jay Sharma, Jitesh Jani, Robert A Hromas, Satya Narayan

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Recently approved chemotherapeutic agents to treat colorectal cancer (CRC) have made some impact; however, there is an urgent need for newer targeted agents and strategies to circumvent CRC growth and metastasis. CRC frequently exhibits natural resistance to chemotherapy and those who do respond initially later acquire drug resistance. A mechanism to potentially sensitize CRC cells is by blocking the DNA polymerase β (Pol-β) activity. Temozolomide (TMZ), an alkylating agent, and other DNA-interacting agents exert DNA damage primarily repaired by a Pol-β -directed base excision repair (BER) pathway. In previous studies, we used structure-based molecular docking of Pol-β and identified a potent small molecule inhibitor (NSC666715). In the present study, we have determined the mechanism by which NSC666715 and its analogs block Fen1-induced strand-displacement activity of Pol-β-directed LP-BER, cause apurinic/apyrimidinic (AP) site accumulation and induce S-phase cell cycle arrest. Induction of S-phase cell cycle arrest leads to senescence and apoptosis of CRC cells through the p53/p21 pathway. Our initial findings also show a 10-fold reduction of the IC50 of TMZ when combined with NSC666715. These results provide a guide for the development of a target-defined strategy for CRC chemotherapy that will be based on the mechanisms of action of NSC666715 and TMZ. This combination strategy can be used as a framework to further reduce the TMZ dosages and resistance in CRC patients.

Original languageEnglish (US)
Article numbere0123808
JournalPLoS One
Volume10
Issue number5
DOIs
StatePublished - May 1 2015
Externally publishedYes

Fingerprint

temozolomide
displacement activities
DNA-directed DNA polymerase
DNA-Directed DNA Polymerase
colorectal neoplasms
DNA damage
DNA Damage
Colorectal Neoplasms
apoptosis
Cells
Apoptosis
Chemotherapy
DNA
Repair
DNA repair
Cell Cycle Checkpoints
Alkylating Agents
S Phase
DNA Repair
interphase

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Agricultural and Biological Sciences(all)

Cite this

NSC666715 and Its analogs inhibit strand-displacement activity of DNA polymerase β and potentiate temozolomide-induced DNA damage, senescence and apoptosis in colorectal cancer cells. / Jaiswal, Aruna S.; Panda, Harekrushna; Law, Brian K.; Sharma, Jay; Jani, Jitesh; Hromas, Robert A; Narayan, Satya.

In: PLoS One, Vol. 10, No. 5, e0123808, 01.05.2015.

Research output: Contribution to journalArticle

@article{03510c5cb2cd4aadad8e908963c1b639,
title = "NSC666715 and Its analogs inhibit strand-displacement activity of DNA polymerase β and potentiate temozolomide-induced DNA damage, senescence and apoptosis in colorectal cancer cells",
abstract = "Recently approved chemotherapeutic agents to treat colorectal cancer (CRC) have made some impact; however, there is an urgent need for newer targeted agents and strategies to circumvent CRC growth and metastasis. CRC frequently exhibits natural resistance to chemotherapy and those who do respond initially later acquire drug resistance. A mechanism to potentially sensitize CRC cells is by blocking the DNA polymerase β (Pol-β) activity. Temozolomide (TMZ), an alkylating agent, and other DNA-interacting agents exert DNA damage primarily repaired by a Pol-β -directed base excision repair (BER) pathway. In previous studies, we used structure-based molecular docking of Pol-β and identified a potent small molecule inhibitor (NSC666715). In the present study, we have determined the mechanism by which NSC666715 and its analogs block Fen1-induced strand-displacement activity of Pol-β-directed LP-BER, cause apurinic/apyrimidinic (AP) site accumulation and induce S-phase cell cycle arrest. Induction of S-phase cell cycle arrest leads to senescence and apoptosis of CRC cells through the p53/p21 pathway. Our initial findings also show a 10-fold reduction of the IC50 of TMZ when combined with NSC666715. These results provide a guide for the development of a target-defined strategy for CRC chemotherapy that will be based on the mechanisms of action of NSC666715 and TMZ. This combination strategy can be used as a framework to further reduce the TMZ dosages and resistance in CRC patients.",
author = "Jaiswal, {Aruna S.} and Harekrushna Panda and Law, {Brian K.} and Jay Sharma and Jitesh Jani and Hromas, {Robert A} and Satya Narayan",
year = "2015",
month = "5",
day = "1",
doi = "10.1371/journal.pone.0123808",
language = "English (US)",
volume = "10",
journal = "PLoS One",
issn = "1932-6203",
publisher = "Public Library of Science",
number = "5",

}

TY - JOUR

T1 - NSC666715 and Its analogs inhibit strand-displacement activity of DNA polymerase β and potentiate temozolomide-induced DNA damage, senescence and apoptosis in colorectal cancer cells

AU - Jaiswal, Aruna S.

AU - Panda, Harekrushna

AU - Law, Brian K.

AU - Sharma, Jay

AU - Jani, Jitesh

AU - Hromas, Robert A

AU - Narayan, Satya

PY - 2015/5/1

Y1 - 2015/5/1

N2 - Recently approved chemotherapeutic agents to treat colorectal cancer (CRC) have made some impact; however, there is an urgent need for newer targeted agents and strategies to circumvent CRC growth and metastasis. CRC frequently exhibits natural resistance to chemotherapy and those who do respond initially later acquire drug resistance. A mechanism to potentially sensitize CRC cells is by blocking the DNA polymerase β (Pol-β) activity. Temozolomide (TMZ), an alkylating agent, and other DNA-interacting agents exert DNA damage primarily repaired by a Pol-β -directed base excision repair (BER) pathway. In previous studies, we used structure-based molecular docking of Pol-β and identified a potent small molecule inhibitor (NSC666715). In the present study, we have determined the mechanism by which NSC666715 and its analogs block Fen1-induced strand-displacement activity of Pol-β-directed LP-BER, cause apurinic/apyrimidinic (AP) site accumulation and induce S-phase cell cycle arrest. Induction of S-phase cell cycle arrest leads to senescence and apoptosis of CRC cells through the p53/p21 pathway. Our initial findings also show a 10-fold reduction of the IC50 of TMZ when combined with NSC666715. These results provide a guide for the development of a target-defined strategy for CRC chemotherapy that will be based on the mechanisms of action of NSC666715 and TMZ. This combination strategy can be used as a framework to further reduce the TMZ dosages and resistance in CRC patients.

AB - Recently approved chemotherapeutic agents to treat colorectal cancer (CRC) have made some impact; however, there is an urgent need for newer targeted agents and strategies to circumvent CRC growth and metastasis. CRC frequently exhibits natural resistance to chemotherapy and those who do respond initially later acquire drug resistance. A mechanism to potentially sensitize CRC cells is by blocking the DNA polymerase β (Pol-β) activity. Temozolomide (TMZ), an alkylating agent, and other DNA-interacting agents exert DNA damage primarily repaired by a Pol-β -directed base excision repair (BER) pathway. In previous studies, we used structure-based molecular docking of Pol-β and identified a potent small molecule inhibitor (NSC666715). In the present study, we have determined the mechanism by which NSC666715 and its analogs block Fen1-induced strand-displacement activity of Pol-β-directed LP-BER, cause apurinic/apyrimidinic (AP) site accumulation and induce S-phase cell cycle arrest. Induction of S-phase cell cycle arrest leads to senescence and apoptosis of CRC cells through the p53/p21 pathway. Our initial findings also show a 10-fold reduction of the IC50 of TMZ when combined with NSC666715. These results provide a guide for the development of a target-defined strategy for CRC chemotherapy that will be based on the mechanisms of action of NSC666715 and TMZ. This combination strategy can be used as a framework to further reduce the TMZ dosages and resistance in CRC patients.

UR - http://www.scopus.com/inward/record.url?scp=84929081895&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84929081895&partnerID=8YFLogxK

U2 - 10.1371/journal.pone.0123808

DO - 10.1371/journal.pone.0123808

M3 - Article

C2 - 25933036

AN - SCOPUS:84929081895

VL - 10

JO - PLoS One

JF - PLoS One

SN - 1932-6203

IS - 5

M1 - e0123808

ER -